Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496750 | 0.90 | HDAC11 (0.46) | HDAC11HDAC8CHRM5MEN1HPGD | |
| SCHEMBL21496705 | 0.87 | HDAC11 (0.46) | HDAC11HDAC8CHRM5GAATDP1 | |
| SCHEMBL21496799 | 0.87 | HDAC11 (0.61) | HDAC11HDAC8 | |
| SCHEMBL21496665 | 0.84 | HDAC11 (0.59) | HDAC11HDAC8SMN1; SMN2 | |
| SCHEMBL23771302 | 0.78 | CHRM5 (0.38) | HDAC11HDAC8CHRM5MEN1HPGD | |
| SCHEMBL21500520 | 0.76 | HDAC11 (0.58) | HDAC11HDAC8CHRM5HPGDCES2 | |
| SCHEMBL29187424 | 0.72 | PARP1 (0.43) | HDAC11HDAC8HPGDTSHRKDM4E | |
| SCHEMBL21496709 | 0.72 | HDAC11 (0.58) | HDAC11HDAC8GAASMN1; SMN2 | |
| SCHEMBL21496849 | 0.72 | HDAC11 (0.74) | HDAC11HDAC8SMN1; SMN2 | |
| SCHEMBL21496686 | 0.71 | HDAC11 (0.69) | HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885CHRM5 2944/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885CHRM5 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.